MediGene AG · LS:A40ESG
MediGene — H1 2010 Earnings Presentation
15 slides from MediGene's earnings presentation, Aug 5, 2010
Slide 1: Analyst and Press Conference Call 6 Months 2010 Financial Results
Analyst and Press Conference Call 6 Months 2010 Financial Results August 5, 2010 Dr. Frank Mathias, CEO Arnd Christ, CFO
Slide 2: Forward-looking statements
This presentation contains forward-looking statements - that is, statements related to future, not past, events. These statements may be identified either orally or in writing by words as "expects", "anticipates", "intents", "plans", "believes", "seeks", "estimates", "will", "may" or words of simila
Slide 3: Recent achievements
Recent achievements
Slide 4: Major achievements in first half of 2010
Major achievements in first half of 2010 Positive results of the phase II clinical trial with EndoTAG™-1 in combination therapy in triple negative breast cancer Further partnerships for marketing Veregen® concluded (Israel, Greece and Cyprus, China and South Korea) Market launch of Veregen® in
Slide 5: Rationale for the Eligard deal: Former situation was very complex
Rationale for the Eligard® deal: Former situation was very complex MediGene was in a sandwich position between the producer and the distributor. Several problems arose from this structure: • Beyond a certain sales level, MediGene’s margin decreased, so MediGene currently did not participate in fur
Slide 6: Sale of European Eligard rights to Astellas
Sale of European Eligard® rights to Astellas Successive payments of a total of € 25 mio.: • € 5 mio. upon signing • € 15 mio. upon transfer of licence for EU countries (within 6-8 months) • € 5 mio. upon transfer of licence for non-EU countries (within 6-12 months) MediGene still receives low si
Slide 7: Financial result 6 months 2010
Financial result 6 months 2010
Slide 8: Total revenue, operating expenses 6M 2010
Total revenue, operating expenses 6M 2010 in € thousand Total revenue Revenue increase mainly driven by Eligard® sales 26% (6M 2010: k€ 23,906; 25,171 6M 2009: k€ 18,440) 19,988 Veregen® sales growing continously 6M 2010 6M 2009 Total in market sales of Veregen® 2010 e: € 6 mio. Veregen® in ma
Slide 9: EBITDA, net loss 6M 2010
EBITDA, net loss 6M 2010 in € thousand EBITDA loss Reduction of EBITDA-loss due to 20% • higher revenues 6,782 5,393 • lower costs 6M 2010 6M 2009 Net loss Positively influenced by • embedded derivative • exchange gains 60% 8,316 • increase of book value of 3,294 MediGene’s stake in 6M 2010 6M 2
Slide 10: Cash flow analysis
Cash flow analysis In € million Development of cash and cash equivalents Cash as of June 30, 2010: 2.2 2.5 € 8.2 mio. 0.3 SEDA Q2-2010: 8.2 8.2 € 2.5 mio. raised (€ 14.4 mio. left) March 31, Operating Investing Financing June 30, 2010 activities activities activities 2010 Monthly cash burn Cas
Slide 11: Outlook
Outlook
Slide 12: Financial outlook for 2010
Financial outlook for 2010 Revenues Depending on the successful transfer of In case the transfer of Eligard® rights the Eligard® rights, MediGene expects to takes place in 2011 only receive € 20 mio. (out of a total of € 25 mio.) from Astellas deal in 2010 Reduced Eligard® revenues upon Full
Slide 13: Outlook for the second half of 2010
Outlook for the second half of 2010 EndoTAG™-1: Conclusion of partnering deal Eligard®: Increasing revenues expected Veregen®: Increasing revenues expected and additional marketing partnerships to be concluded RhuDex®: Evaluation of preclinical trial results as basis for resumption of clinic
Slide 14: Questions & Answers
Questions & Answers Dr. Frank Mathias, CEO Arnd Christ, CFO
Slide 15: MediGene AG
MediGene AG Lochhamer Straße 11 82152 Planegg / Martinsried, Germany Phone: +49 89 85 65 29 00 Fax: +49 89 85 65 29 20 www.medigene.com